BioXCell的中和/阻斷抗體受到國(guó)內(nèi)外研究者的普遍熱愛和青睞，在腫瘤、癌癥等方面的研究中廣受好評(píng)。BioXCell公司位于美國(guó)新罕布什爾州，具有25年以上單克隆抗體和重組蛋白的生產(chǎn)及定制經(jīng)驗(yàn)，可提供高純度、低內(nèi)毒素、無防腐劑、適用于體內(nèi)臨床前研究的單克隆抗體。
 |
高純度、低內(nèi)毒素，無防腐劑，適用于體內(nèi)臨床前研究 |
| 超過二十五年單克隆抗體和重組蛋白生產(chǎn)及定制經(jīng)驗(yàn) | |
| 性價(jià)比高，可提供100mg甚至50g的大包裝 | |
| 超過15000篇高質(zhì)量期刊文獻(xiàn)引用 |
腫瘤癌癥免疫治療應(yīng)用
●抑制免疫檢查點(diǎn)和其他免疫調(diào)節(jié)來治療惡性腫瘤是現(xiàn)在利用免疫系統(tǒng)殺死腫瘤細(xì)胞的有力途徑。BioXCell提供三種不同克隆號(hào)的anti mouse PD-1抗體：RMP1-14、29F.1A12和J43。三種抗體都通過相同的機(jī)制發(fā)揮作用—它們結(jié)合PD-1，并在空間上阻斷PD-1與PD-1配體的結(jié)合，從而阻斷PD-1信號(hào)傳導(dǎo)。這三種克隆號(hào)的抗體都非常適合在小鼠體內(nèi)模型中阻斷PD-1信號(hào)傳導(dǎo)，并有大量文獻(xiàn)支持這一應(yīng)用。這些抗體之間的差異在于文獻(xiàn)報(bào)道中的其他應(yīng)用、Isotype和來源。
●通過用阻斷PD-L1和它的受體PD-1之間的相互作用的抗體治療，腫瘤生長(zhǎng)可以暫時(shí)被抑制。
●抗PD-1聯(lián)合抗CTLA-4抗體介導(dǎo)的免疫治療對(duì)黑色素瘤、腎細(xì)胞癌和非小細(xì)胞肺癌具有顯著療效。
●通過靶向調(diào)節(jié)免疫反應(yīng)的途徑，如RANK途徑，可以將“cold”腫瘤轉(zhuǎn)化為“hot”腫瘤。使用Bio X Cell’s Anti-mouse RANKL (clone IK22/5) antibody，研究人員證明了對(duì)RANK通路的抑制將“cold”乳腺腫瘤轉(zhuǎn)化為“hot”腫瘤，變?yōu)?ldquo;hot”的腫瘤可能受益于免疫療法。
腫瘤研究相關(guān)的抗體
| 抗體指標(biāo) | 應(yīng)用 | 克隆號(hào) | InVivoMab | InVivoPlus | 同型對(duì)照 | 稀釋液 |
| Anti mouse PD-1(CD279) | In vivo blocking of PD-1/PD-L signaling | RMP1-14 | BE0146 | BP0146 | BE0089 | IP0070 |
| In vivo blocking of PD-1/PD-L signaling In vitro PD-1 neutralization IHC-Fr/Immunofluorescence/WB/FC |
29F.1A12 | BE0273 | BP0273 | BE0089 | IP0070 | |
| In vivo blocking of PD-1/PD-L signaling In vitro PD-1 neutralization WB |
J43 | BE0033-2 | BP0033-2 | BE0091 | IP0065 | |
| Anti mouse PD-L1(B7-H1) | In vivo PD-L1 blockade IHC-Fr/Immunofluorescence/WB/FC |
10F.9G2 | BE0101 | BP0101 | BE0090 | IP0065 |
| Anti mouse CTLA-4 (CD152) | In vivo CTLA-4 neutralization WB |
9D9 | BE0164 | BP0164 | BE0086 | IP0070 |
| In vivo CTLA-4 neutralization In vitro CTLA-4 neutralization WB |
9H10 | BE0131 | BP0131 | BE0087 | IP0070 | |
| In vivo CTLA-4 neutralization In vitro CTLA-4 neutralization WB/FC |
UC10-4F10-11 | BE0032 | BP0032 | BE0091 | IP0065 | |
| Anti mouse CD4 | In vivo CD4+ T cell depletion WB/FC |
GK1.5 | BE0003-1 | BP0003-1 | BE0090 | IP0065 |
| Anti mouse CD8α | In vivo CD8+ T cell depletion Immunofluorescence/WB/FC |
53-6.7 | BE0004-1 | BP0004-1 | BE0089 | IP0065 |
| In vivo CD8+ T cell depletion WB |
2.43 | BE0061 | BP0061 | BE0090 | IP0070 | |
| In vivo CD8+ T cell depletion WB |
YTS 169.4 | BE0117 | BP0117 | BE0090 | IP0070 | |
| Anti mouse Ly6G | In vivo neutrophil depletion In vivo MDSC depletion IHC-P/IHC-Fr/IF/FC |
1A8 | BE0075-1 | BP0075-1 | BE0089 | IP0065 |
| Anti mouse Ly6G/Ly6C (Gr-1) | In vivo depletion of Gr-1+ myeloid cells IHC-P/IHC-Fr/FC |
RB6-8C5 | BE0075 | BP0075 | BE0090 | IP0070 |
| Anti mouse IFNγ | In vivo IFN-γ neutralization In vitro IFN-γ neutralization ELISPOT/WB/FC |
XMG1.2 | BE0055 | BP0055 | BE0088 | IPT080 |
| Anti mouse IFNAR-1 | In vivo IFNAR-1 blockade In vitro IFNAR-1 blockade WB |
MAR1-5A3 | BE0241 | BP0241 | BE0083 | IP0070 |
|
Anti-mouse/human/rat/monkey/hamster/ canine/bovine TGF-β |
In vivo TGF-β neutralization In vitro TGF-β neutralization WB |
1D11.16.8 | BE0057 | BP0057 | BE0083 | IP0070 |
| Anti mouse CD28 | In vitro T cell stimulation/activation In vivo CD28 blockade |
37.51 | BE0015-1 | / | BE0087 | IPT060 |
| in vitro T cell stimulation/activation | PV-1 | BE0015-5 | / | BE0091 | IP0070 | |
| Anti mouse CD3ε | In vitro T cell stimulation/activation In vivo T cell depletion Immunofluorescence/WB/FC |
145-2C11 | BE0001-1 | BP0001-1 | BE0091 | IP0070 |
| Anti-human CD3 | In vitro T cell stimulation/activation In vivo T cell depletion in humanized mice Ex vivo T cell inhibition for xenografts FC |
OKT-3 | BE0001-2 | / | BE0085 | IP0070 |
| Anti mouse CD40 | In vivo CD40 activation In vitro B cell stimulation/activation |
FGK4.5/ FGK45 | BE0016-2 | BP0016-2 | BE0089 | IP0070 |
| Anti mouse CD154 (CD40L) | In vivo blocking of CD40/CD40L signaling In vitro blocking of CD40/CD40L signaling WB |
MR-1 | BE0017-1 | BP0017-1 | BE0091 | IP0070 |
| Anti mouse CD25 (IL-2Rα) | In vivo regulatory T cell depletion FC |
PC-61.5.3 | BE0012 | BP0012 | BE0088 | IP0070 |
| Anti mouse IL-4 | In vivo IL-4 neutralization In vitro IL-4 neutralization In vivo IL-4 receptor stimulation (as a complex with IL-4) FC/WB |
11B11 | BE0045 | BP0045 | BE0088 | IP0070 |
| Anti mouse NK1.1 | In vivo NK cell depletion FC |
PK136 | BE0036 | BP0036 | BE0085 | IP0070 |
| Anti mouse CSF1R (CD115) | In vivo macrophage depletion In vitro CSF1R neutralization In vivo monocyte depletion FC/WB |
AFS98 | BE0213 | BP0213 | BE0089 | IP0070 |
| Anti mouse CD25 (IL-2Rα) | In vivo regulatory T cell depletion FC |
PC-61.5.3 | BE0012 | BP0012 | BE0088 | IP0070 |
| anti-mouse OX40 (CD134) | In vivo OX40 activation In vitro OX40 activation WB |
OX-86 | BE0031 | BP0031 | BE0088 | IP0070 |
暢銷同型對(duì)照抗體
| 同型對(duì)照 | InVivoMab | InVivoPlus |
| 目錄號(hào) | 目錄號(hào) | |
| Rat IgG2a Isotype control, FC | BE0089 | BP0089 |
| Rat IgG2b Isotype control | BE0090 | BP0090 |
| Mouse IgG1 Isotype control | BE0083 | BP0083 |
| Rat IgG1 Isotype control | BE0088 | BP0088 |
| Mouse IgG2a Isotype control | BE0085 | BP0085 |
| Mouse IgG2b Isotype control | BE0086 | BP0086 |
| Polyclonal Armenian Hamster IgG | BE0091 | BP0091 |
InVivoPlus™ Vs InVivoMab™系列之間區(qū)別
| InVivoMab | InVivoPlus | |
| 純度 | > 95% | > 95% |
| 蛋白完整性 | √ (verified via SDS-PAGE) | √ü(verified via SDS-PAGE) |
| 內(nèi)毒素濃度 | < 2EU/mg | < 1EU/mg |
| 不含疊氮化物和載體蛋白 | √ | √ |
| 是否適用于體內(nèi)研究 | √ | √ |
| 是否提供大包裝 | √ | √ |
| 是否經(jīng)WB, FC或ELISA驗(yàn)證 | √ | |
| 經(jīng)驗(yàn)證蛋白聚集≤ 5% | √ | |
| 是否經(jīng)過鼠科病原體檢測(cè) | √ | |
| 產(chǎn)品貨號(hào) | BE-開頭 | BP-開頭 |
BioXCell的RecombiMAb系列抗體
BioXCell的RecombiMAb系列抗體是新開發(fā)的重組單克隆抗體，具有與其傳統(tǒng)克隆號(hào)來源相同的抗原結(jié)合可變區(qū)，但I(xiàn)gG恒定區(qū)已從大鼠或倉(cāng)鼠IgG變?yōu)樾∈蠡蛉薎gG。這意味著對(duì)于小鼠模型或人源化小鼠模型的免疫原性降低。
RecombiMAb單克隆抗體
| 產(chǎn)品名稱 | 宿主 | 亞型 | 貨號(hào) | 同型對(duì)照 | 稀釋液 | 應(yīng)用 |
| Anti-Mouse PD-1 (CD279) (D265A) | Mouse | IgG2a, Κ | CP151 | CP150 | IP0070 | in vivo blocking of PD-1/PD-L signaling |
| Anti-Mouse CTLA-4 (CD152) | Mouse | IgG1, Κ | CP146 | BP0083 | IP0070 | In vivo CTLA-4 neutralization In vitro CTLA-4 neutralization WB |
| Human IgG4 (S228P) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG4, Κ | CP147 | - | - | - |
| Human IgG4 S228P L235E P329G (SPLEPG) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG4 | CP148 | - | - | - |
| Human IgG1 (LALA-PG) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG1 | CP149 | - | - | - |
| Mouse IgG2a (D265A) Isotype Control, Anti-Hen Egg Lysozyme | Mouse | IgG2a | CP150 | - | - | - |
BioXCell的重組融合蛋白
融合蛋白即通過將細(xì)胞表面受體的結(jié)合域與抗體的Fc部分結(jié)合而形成，這樣可以使得配體分子不會(huì)結(jié)合到內(nèi)源性受體，從而阻斷受體信號(hào)的傳導(dǎo)。蛋白純度大于95%，內(nèi)毒素水平超低，不含防腐劑、穩(wěn)定劑和載體蛋白等試劑，專為體內(nèi)研究而開發(fā)。
| 貨號(hào) | 產(chǎn)品名稱 | 貨號(hào) | 產(chǎn)品名稱 | 規(guī)格 |
| BE0099 | InVivoMAb recombinant CTLA-4-lg | BP0099 | InVivoPlus recombinant CTLA-4-Ig | 5mg，25mg，50mg，100mg |
| BE0098 | InVivoMAb recombinant Flt-3L-lg | BE0148 | InVivoMAb recombinant Mouse Angiostatin-lg | 5mg，25mg，50mg，100mg |
| BE0149 | InVivoMAb recombinant Mouse Endostatin-lg | - | - | 5mg，25mg，50mg，100mg |
產(chǎn)品示例(圖片)：
